Open access

353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC
Antonio Jimeno, Sophie Papa, Missak Haigentz, Juan Rodríguez-Moreno, Julian Schardt, Maria Fardis, Friedrich Graf Finckenstein, Rana Fiaz, Guang Chen, Alex Cacovean, Zelanna Goldberg, Ammar Sukari

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A215-A216; DOI: 10.1136/jitc-2020-SITC2020.0353
354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
Sara Pai, Douglas Adkins, Lori Wirth, Christine Chung, Michael Gibson, Ammar Sukari, Francis Worden, Dimitrios Colevas, Nabil Saba, Barbara Burtness, Cristina Rodriguez, Julie Bauman, Bonnie Glisson, Lara Dunn, Anish Suri, Mark Haydock, Steven Quayle, Saso Cemerski, Megan Leader, Jason Brown, Kenneth Pienta, Mary Simcox

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A216; DOI: 10.1136/jitc-2020-SITC2020.0354
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
Nina Shah, Alan Tan, Lihua Budde, Craig Hofmeister, Andrew Cowan, Hayder Saeed, Jing Ye, Mitchell Cairo, David Rizzieri, Gregory Orloff, Xue Snow Ge, Zachary Lee, Neha Dixit, Wildaliz Nieves, Mona Vimal, Haijun Ma, Takahiro Miyazaki, Loui Madakamutil, Mario Marcondes, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Krina Patel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A216-A217; DOI: 10.1136/jitc-2020-SITC2020.0355
402 DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone
Lu Gan, Johanna Bendell

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A244-A245; DOI: 10.1136/jitc-2020-SITC2020.0402
423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
Steven O’Day, Cesar Perez, Trisha Wise-Draper, Glenn Hanna, Shailender Bhatia, Ciara Kelly, Theresa Medina, Douglas Laux, Adil Daud, Sunandana Chandra, Montaser Shaheen, Ling Gao, Melissa Burgess, Leonel Hernandez-Aya, Cecilia Yeung, Kimberly Smythe, Emil DeGoma, Weston Daniel, Douglas Feltner, Laurel Sindelar, Robert Michel, Alice Bexon, Martin Bexon, Mohammed Milhem

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A257-A258; DOI: 10.1136/jitc-2020-SITC2020.0423
425 Investigation of Wnt ligand signaling regulators as a predictor of Anti-PD-1 response in metastatic melanoma
Nicholas DeVito, Michael Sturdivant, Luke Wachsmuth, John Strickler, Georgia Beasley, Rami Al-Rohil, April Salama, Brent Hanks

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A258-A259; DOI: 10.1136/jitc-2020-SITC2020.0425
432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
Reinhard Dummer, David Gyorki, John Hyngstrom, Adam Berger, Robert Conry, Lev Demidov, Edward Chan, Hoi-Shen Radcliffe, Mark Faries, Merrick Ross

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A263; DOI: 10.1136/jitc-2020-SITC2020.0432
436 Rational sequencing of immune-oncology therapies achieves durable response and immunologic memory
Robert Saddawi-Konefka, Aoife O’Farrell, Andrew Sharabi, Joseph Califano, J Silvio Gutkind, Robert Saddawi-Konefka

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A265-A266; DOI: 10.1136/jitc-2020-SITC2020.0436
439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity
Catherine Sabatos-Peyton, Tyler Longmire, Lisa Baker, Nidhi Patel, Anne-Sophie Wavreille, Melanie Verneret, Pushpa Jayaraman, Xiaomo Jiang, Stephanie Schwartz, Viviana Cremasco, Hongbo Lu, Shumei Qiu, Fiona Sharp, Mikael Rinne, Glenn Dranoff

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A267; DOI: 10.1136/jitc-2020-SITC2020.0439
440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer
Guo Gui Sun, Jing Hao Jia, Peng Gao, Xue Min Yao, Ming Da Chen, Wei Nan Yao, Lu Sun, Wei Wang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A267-A268; DOI: 10.1136/jitc-2020-SITC2020.0440

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages